Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3390/ijms21207496

http://scihub22266oqcxt.onion/10.3390/ijms21207496
suck pdf from google scholar
33053650!7589779!33053650
unlimited free pdf from europmc33053650    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid33053650      Int+J+Mol+Sci 2020 ; 21 (20): ä
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Toward Drug-Like Multispecific Antibodies by Design #MMPMID33053650
  • Sawant MS; Streu CN; Wu L; Tessier PM
  • Int J Mol Sci 2020[Oct]; 21 (20): ä PMID33053650show ga
  • The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is not optimal for many therapeutic applications, and this has led to the design of a vast number of unique multispecific antibody formats that enable targeting of multiple antigens or multiple epitopes on the same antigen. Despite the diversity of these formats, a common challenge in generating multispecific antibodies is that they display suboptimal physical and chemical properties relative to conventional IgGs and are more difficult to develop into therapeutics. Here we review advances in the design and engineering of multispecific antibodies with drug-like properties, including favorable stability, solubility, viscosity, specificity and pharmacokinetic properties. We also highlight emerging experimental and computational methods for improving the next generation of multispecific antibodies, as well as their constituent antibody fragments, with natural IgG-like properties. Finally, we identify several outstanding challenges that need to be addressed to increase the success of multispecific antibodies in the clinic.
  • |*Antibody Specificity/immunology[MESH]
  • |*Drug Design[MESH]
  • |*Protein Engineering[MESH]
  • |Animals[MESH]
  • |Antibodies, Bispecific/*chemistry/genetics/immunology/*pharmacology[MESH]
  • |Antibodies, Monoclonal/*chemistry/genetics/immunology/*pharmacology[MESH]
  • |Antibody Affinity/immunology[MESH]
  • |Chemical Phenomena[MESH]
  • |Drug Development[MESH]
  • |Drug Stability[MESH]
  • |Humans[MESH]
  • |Models, Molecular[MESH]
  • |Solubility[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box